Cencora Inc. stock gains on Morgan Stanley conference growth message
Published on 09/16/2026 at 14:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Cencora Inc. stock (ISIN US15135B1017) was recently quoted at about USD 323.20 on the New York Stock Exchange as of September 16, 2026, with the shares trading in the upper half of their 52-week range between USD 244.82 and USD 377.54.
Specialty strategy and conference highlight
Cencora Inc. used its appearance at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026 to underline that its specialty pharmaceuticals strategy and healthcare solutions businesses are driving growth for the group, with management pointing to adjusted operating income growth of 14.5 percent to 15.5 percent in the Healthcare Solutions segment ahead of the company’s long-term profile, according to Investing.com on September 15, 2026.
At the same conference, Cencora representatives reaffirmed the company’s longstanding strategic partnership with Walgreens and described how this relationship supports its specialty distribution network and broader healthcare solutions offering, as reported by GuruFocus on September 15, 2026.
Latest earnings and growth figures
Cencora Inc. last reported quarterly results for a fiscal quarter ended in early August 2026, with the company posting earnings per share of USD 4.48, which exceeded the analyst consensus estimate of USD 4.35 by USD 0.13 according to MarketBeat on September 16, 2026.
In the same quarter, Cencora generated revenue of USD 84.75 billion, slightly ahead of the USD 84.31 billion that analysts had expected, with revenue up 5.1 percent compared with the same quarter a year earlier, again based on data from MarketBeat on September 16, 2026.
The earnings report also showed that Cencora recorded a return on equity of 125.45 percent and a net margin of 0.79 percent for that quarter, illustrating how a relatively thin margin business can still deliver strong equity returns when paired with very high revenue volumes, according to MarketBeat on September 16, 2026.
Analyst view and valuation context
Analysts covering Cencora Inc. currently assign the shares a consensus rating of Moderate Buy, with 13 buy ratings and 3 hold ratings and no sell recommendations, and see a consensus price target of USD 370.85, implying roughly 14.6 percent upside from a recent price level around USD 323.48, based on data from MarketBeat as of September 15, 2026.
From a valuation perspective, one proprietary model from GuruFocus estimates Cencora’s intrinsic value at USD 303.87 per share, with the shares trading at USD 322.06 on September 15, 2026, which places the stock about 6.0 percent above that GF Value metric and suggests Cencora Inc. stock is fairly valued but carries a modest valuation premium, as GuruFocus reported on September 15, 2026.
Stock level and trading range
Per recent NYSE data summarized by MarketBeat, Cencora Inc. stock has traded in a 52-week range between USD 244.82 and USD 377.54, with the latest quoted level around USD 323.20 placing the share price roughly in the upper half of that band and leaving the stock about 14.6 percent below the consensus price target of USD 370.85 but still below the 52-week high of USD 377.54, according to MarketBeat on September 15, 2026.
MarketBeat data place Cencora’s market capitalization at USD 61.68 billion as of mid-September 2026, with average daily trading volume around 1.50 million shares and a recent session volume of approximately 913,440 shares, figures that indicate a liquid stock whose price can still respond meaningfully to new information such as conference commentary and quarterly results, based on MarketBeat as of September 15, 2026.
Closing price context for investors
At a recent closing price near USD 323.20 on the New York Stock Exchange as of September 16, 2026, Cencora Inc. stock trades below both its 52-week high of USD 377.54 and the analyst consensus price target of USD 370.85, leaving a quantified gap that investors can weigh against the company’s demonstrated revenue growth of 5.1 percent year on year and its adjusted operating income growth ambitions of 14.5 percent to 15.5 percent in its Healthcare Solutions business.
Cencora Inc. stock - key data
- Company: Cencora Inc.
- ISIN: US15135B1017
- Ticker: COR
- Trading venue: NYSE
- Price (as of September 16, 2026): 323.20 USD
- Market capitalization: 61.68 billion USD (as of September 15, 2026)
- Sector / Industry: Healthcare distribution and services
- Index membership: S&P 500
